These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 3726512)

  • 1. [Parkinson therapy 1985].
    Kaeser HE
    Schweiz Med Wochenschr; 1986 Jun; 116(24):801-4. PubMed ID: 3726512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dyskinesia caused by L-DOPA].
    Derkinderen P; Vidailhet M
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current developments in the long-term therapy of Parkinson syndrome].
    Ludin HP
    Schweiz Rundsch Med Prax; 1992 Nov; 81(48):1458-60. PubMed ID: 1448642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long-term therapy of the Parkinson syndrome].
    Ludin HP
    Schweiz Med Wochenschr; 1984 Aug; 114(33):1131-6. PubMed ID: 6484543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of treatment with levodopa on Parkinson's disease.
    Shaw KM; Lees AJ; Stern GM
    Q J Med; 1980; 49(195):283-93. PubMed ID: 7465763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioids and motor complications in Parkinson's disease.
    Samadi P; Bédard PJ; Rouillard C
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current preclinical findings on substances against Parkinson's disease].
    Gerlach M; Riederer P
    Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.
    Obering CD; Chen JJ; Swope DM
    Pharmacotherapy; 2006 Jun; 26(6):840-52. PubMed ID: 16716137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical aspects and conservative therapy of Parkinson disease].
    Dengler R
    Zentralbl Neurochir; 1995; 56(4):148-52. PubMed ID: 8571692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
    Caraceni T; Giovannini P; Girotti F; Parati E; Pederzoli M; Scigliano G
    Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pergolide in late-stage Parkinson disease.
    Lang AE; Quinn N; Brincat S; Marsden CD; Parkes JD
    Ann Neurol; 1982 Sep; 12(3):243-7. PubMed ID: 6753730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.